Association of interleukin-10 polymorphisms with risk of irritable bowel syndrome: A meta-analysis

Table 1 Characteristic of individual studies in the meta-analysis

Ref.	Year	Country/ethnicity	SNP of IL-10	IBS/controls	Genotyping methods	Diagnostic criteria	HWE of control
Gonsalkorale et al[21]	2003	United Kingdom	rs1800870	230/450	PCR-SSP	Rome I	0.000
van der Veek et al[13]	2005	Netherlands	rs1800870	111/128	PCR-RFLP	Rome II	0.707
Wang et al[24]	2006	China	rs1800870	43/41	PCR-RFLP	Rome II	0.678
Barkhordari et al[18]	2010	Iran	rs1800870	70/140	PCR-SSP	Rome III	0.041
Lee et al[22]	2010	South Korea	rs1800870	94/88	PCR-RFLP	Rome III	0.707
Santhosh et al[23]	2010	Indian	rs1800870	23/20	PCR-SSP	Rome II	0.717
Romero-Valdovinos et al[20]	2012	Mexico	rs1800870	45/173	PCR-RFLP	Rome III	0.000
Wang et al[24]	2006	China	rs1800871	43/41	PCR-RFLP	Rome II	0.619
Barkhordari et al[18]	2010	Iran	rs1800871	70/140	PCR-SSP	Rome III	0.907
Santhosh et al[23]	2010	China	rs1800871	23/20	PCR-SSP	Rome II	0.662
Romero-Valdovinos et al[20]	2012	Mexico	rs1800871	45/173	PCR-RFLP	Rome III	0.920
Wang et al[24]	2006	China	rs1800872	43/41	ARMS-PCR	Rome II	0.619
Barkhordari et al[18]	2010	Iran	rs1800872	70/140	PCR-RFLP	Rome III	0.97
Jiang et al[32]	2010	China	rs1800872	312/325	PCR-SSP	Rome III	0.255
Santhosh et al[23]	2010	Indian	rs1800872	23/20	PCR-SSP	Rome II	0.438
Romero-Valdovinos et al[20]	2012	Mexico	rs1800872	45/173	PCR-RFLP	Rome III	0.018

SNP: Single nucleotide polymorphism; HWE: Hardy-Weinberg equilibrium; IBS: Irritable bowel syndrome; PCR: Polymerase chain reaction; SSP: Sequence specific primer; RFLP: Restriction fragment length polymorphism; ARMS: Amplification refractory mutation system.